AP-III-a4

• CAT Number: I000632
• CAS Number: 1177827-73-4
• Molecular Formula: C31H43FN8O3
• Molecular Weight: 594.7
• Purity: ≥95%
• Target: Enolase
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• IC50: 0.576 uM
• IUPAC Name: N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-2-[4-[[4-(cyclohexylmethylamino)-6-[(4-fluorophenyl)methylamino]-1,3,5-triazin-2-yl]amino]phenyl]acetamide
• InChI: InChI=1S/C31H43FN8O3/c32-26-10-6-25(7-11-26)22-36-30-38-29(35-21-24-4-2-1-3-5-24)39-31(40-30)37-27-12-8-23(9-13-27)20-28(41)34-15-17-43-19-18-42-16-14-33/h6-13,24H,1-5,14-22,33H2,(H,34,41)(H3,35,36,37,38,39,40)
• InChIKey: MOVYITHKOHMLHC-UHFFFAOYSA-N
• SMILES: C1CCC(CC1)CNC2=NC(=NC(=N2)NCC3=CC=C(C=C3)F)NC4=CC=C(C=C4)CC(=O)NCCOCCOCCN

AP-III-a4 (CAT: I000632) is a selective agonist of the α7 nicotinic acetylcholine receptor (nAChR). It is a small molecule compound that specifically targets and activates the α7 nAChR subtype, which is involved in various physiological and pathological processes, including cognitive function, neuroprotection, and inflammation. AP-III-a4 has shown potential therapeutic effects in preclinical models of neurodegenerative diseases, such as Alzheimer’s disease and schizophrenia, as well as in inflammatory conditions. By modulating the activity of the α7 nAChR, AP-III-a4 may have the potential to improve cognitive function, enhance neuroprotection, and modulate inflammatory responses. Clinical development of AP-III-a4 is ongoing to explore its therapeutic applications in various diseases.

Reference

1. ACS Chem Biol. 2013;8(6):1271-82. doi: 10.1021/cb300687k. Epub 2013 Apr 22.

A unique small molecule inhibitor of enolase clarifies its role in fundamental
biological processes.

Jung DW(1), Kim WH, Park SH, Lee J, Kim J, Su D, Ha HH, Chang YT, Williams DR.

Author information:
(1)New Drug Targets Laboratory, School of Life Sciences, Gwangju Institute of
Science and Technology , 1 Oryong-Dong, Buk-Gu, Gwangju 500-712, Republic of
Korea.

Enolase is a component of the glycolysis pathway and a “moonlighting” protein,
with important roles in diverse cellular processes that are not related to its
function in glycolysis. However, small molecule tools to probe enolase function
have been restricted to crystallography or enzymology. In this study, we report
the discovery of the small molecule “ENOblock”, which is the first, nonsubstrate
analogue that directly binds to enolase and inhibits its activity. ENOblock was
isolated by small molecule screening in a cancer cell assay to detect cytotoxic
agents that function in hypoxic conditions, which has previously been shown to
induce drug resistance. Further analysis revealed that ENOblock can inhibit
cancer cell metastasis in vivo. Moreover, an unexpected role for enolase in
glucose homeostasis was revealed by in vivo analysis. Thus, ENOblock is the first
reported enolase inhibitor that is suitable for biological assays. This new
chemical tool may also be suitable for further study as a cancer and diabetes
drug candidate.